Appili Therapeutics
Financials
Estimates*
CAD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | <1m | - | 1.4m | <1m | <1m | - | - |
% growth | (40 %) | - | - | (76 %) | 148 % | - | - |
EBITDA | (5.4m) | (14.2m) | (23.5m) | (7.7m) | (2.1m) | - | - |
% EBITDA margin | (2705 %) | - | (1691 %) | (2316 %) | (258 %) | - | - |
Profit | (5.4m) | (14.3m) | (25.1m) | (9.2m) | (3.8m) | (10.3m) | (10.7m) |
% profit margin | (2720 %) | - | (1806 %) | (2766 %) | (457 %) | - | - |
EV / revenue | 110.6x | - | 4.9x | 30.1x | 14.9x | - | - |
EV / EBITDA | -4.1x | -3.8x | -0.3x | -1.3x | -5.8x | - | - |
R&D budget | 3.0m | 10.9m | 21.5m | 3.8m | 5.8m | - | - |
R&D % of revenue | 1517 % | - | 1543 % | 1140 % | 705 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $3.3m | Seed | |
CAD2.2m | Seed | ||
$3.1m | Seed | ||
$4.3m | Seed | ||
N/A | $3.6m | Early VC | |
N/A | N/A | IPO | |
* | N/A | CAD10.3m | Post IPO Equity |
$15.5m | Post IPO Equity | ||
* | CAD1.4m | Private Placement VC | |
$3.5m | Post IPO Convertible | ||
$1.0m | Post IPO Equity | ||
N/A | $7.0m | Post IPO Equity | |
CAD12.7m | Grant | ||
* | N/A | CAD4.5m | Post IPO Equity |
* | CAD2.5m | Post IPO Debt | |
* | CAD300k | Post IPO Debt | |
* | N/A | Acquisition | |
* | CAD300k | Post IPO Debt | |
Total Funding | €23.9m |
Recent News about Appili Therapeutics
EditAppili Therapeutics, based in Nova Scotia, Canada, is dedicated to developing innovative drug programs to address unmet patient needs across a broad spectrum of infectious diseases. The company operates in the pharmaceutical and biotechnology market, focusing on creating solutions for serious global challenges in infectious diseases. Appili serves a diverse range of clients including patients, healthcare providers, and society at large. The business model revolves around active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization. Revenue is generated through the development and commercialization of its drug programs, as well as through strategic partnerships and licensing agreements. The leadership team is highly skilled in advancing programs with significant potential, ensuring that the company remains at the forefront of infectious disease treatment innovation.
Keywords: infectious diseases, drug development, unmet needs, global health, biotechnology, pharmaceutical, commercialization, clinical programs, partnerships, innovation.